These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 162676)

  • 1. A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
    Murphy JE; Donald JF; Molla AL; Crowder D
    J Int Med Res; 1975; 3(3):202-6. PubMed ID: 162676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three controlled trials of weight loss with phenylpropanolamine.
    Altschuler S; Conte A; Sebok M; Marlin RL; Winick C
    Int J Obes; 1982; 6(6):549-56. PubMed ID: 6761288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity.
    Arterburn D
    Clin Evid; 2003 Dec; (10):676-89. PubMed ID: 15555115
    [No Abstract]   [Full Text] [Related]  

  • 4. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
    Evans ER; Wallace MG
    Curr Med Res Opin; 1975; 3(3):132-7. PubMed ID: 1149481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diethylpropion and mazindol: An end to the discussion?
    Lucchetta RC; Riveros BS; Pontarolo R; Radominski RB; Otuki MF; Fernandez-Llimos F; Correr CJ
    Rev Assoc Med Bras (1992); 2017 Mar; 63(3):203-206. PubMed ID: 28489121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double blind evaluation of long acting diethylpropion hydrochloride in obese patients from a general practice.
    Carney DE; Tweddell ED
    Med J Aust; 1975 Jan; 1(1):13-5. PubMed ID: 1092973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
    Lucchetta RC; Riveros BS; Pontarolo R; Radominski RB; Otuki MF; Fernandez-Llimos F; Correr CJ
    Clinics (Sao Paulo); 2017 May; 72(5):317-324. PubMed ID: 28591345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    Suplicy H; Boguszewski CL; dos Santos CM; do Desterro de Figueiredo M; Cunha DR; Radominski R
    Int J Obes (Lond); 2014 Aug; 38(8):1097-103. PubMed ID: 24287940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
    Mies R
    Med Klin; 1976 Nov; 71(46):2013-6. PubMed ID: 995040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of obesity: cost-benefit assessment of behavioral therapy, placebo, and two anorectic drugs.
    Dahms WT; Molitch ME; Bray GA; Greenway FL; Atkinson RL; Hamilton K
    Am J Clin Nutr; 1978 May; 31(5):774-8. PubMed ID: 417615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.
    Vallé-Jones JC; Brodie NH; O'Hara H; O'Hara J; McGhie RL
    Pharmatherapeutica; 1983; 3(5):300-4. PubMed ID: 6844367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled-release diethylpropion hydrochloride used in a program for weight reduction.
    Parsons WB
    Clin Ther; 1981; 3(5):329-35. PubMed ID: 7471128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mazindol (Teronac) in the treatment of predominant by food-dependent obesity].
    Husmann F
    Med Welt; 1976 Oct; 27(40):1904-8. PubMed ID: 790077
    [No Abstract]   [Full Text] [Related]  

  • 15. Mazindol (Teronac)- another anorectic drug.
    Drug Ther Bull; 1974 Dec; 12(26):101-2. PubMed ID: 4459058
    [No Abstract]   [Full Text] [Related]  

  • 16. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.
    Cercato C; Roizenblatt VA; Leança CC; Segal A; Lopes Filho AP; Mancini MC; Halpern A
    Int J Obes (Lond); 2009 Aug; 33(8):857-65. PubMed ID: 19564877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diethylpropion in the treatment of obese patients seen in general practice.
    Matthews PA
    Curr Ther Res Clin Exp; 1975 Apr; 17(4):340-6. PubMed ID: 804381
    [No Abstract]   [Full Text] [Related]  

  • 19. Obesity.
    Arterburn D; DeLaet D; Flum D
    Clin Evid; 2005 Jun; (13):707-25. PubMed ID: 16135277
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind controlled study of the use of diethylpropion hydrochloride (Tenuate) in obese patients in a rural practice.
    Elliott BJ
    N Z Med J; 1978 Oct; 88(622):321-2. PubMed ID: 282482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.